Question 1

Can I get Mounjaro for weight loss if I don't have diabetes?

Accepted Answer

Rarely. Mounjaro's FDA label is type 2 diabetes only — commercial insurance prior-authorization criteria require a documented A1c >=6.5% (or established T2D diagnosis) plus typically a metformin trial. Without a T2D diagnosis, almost all plans deny Mounjaro and direct the patient to Zepbound (same molecule, obesity label) or Wegovy (semaglutide, obesity label). Off-label cash prescribing exists but runs ~$1,000-$1,100/mo retail with no manufacturer cash-pay tier comparable to Wegovy's NovoCare or Zepbound's LillyDirect.

Question 2

Which has stronger weight-loss data, Mounjaro or Wegovy?

Accepted Answer

The tirzepatide molecule (Mounjaro/Zepbound) beats the semaglutide molecule (Wegovy) head-to-head. SURMOUNT-5 (Aronne 2025 NEJM, PMID 40353578) randomized 751 adults with obesity to tirzepatide vs semaglutide and showed -20.2% body weight vs -13.7% at 72 weeks — a 6.5-percentage-point gap. Note SURMOUNT-5 used Zepbound and Wegovy dosing (max 15 mg tirzepatide vs 2.4 mg semaglutide), not Mounjaro's T2D dosing — but Mounjaro and Zepbound are the same molecule at the same doses.

Question 3

Why does my doctor prescribe Wegovy instead of Mounjaro for obesity?

Accepted Answer

Because Wegovy carries the FDA-labeled indication for chronic weight management and Mounjaro does not. Prescribing Mounjaro for obesity is off-label and rarely covered by commercial insurance — payer formularies typically tie Mounjaro coverage to a T2D diagnosis (A1c >=6.5%). Wegovy's labeled obesity indication unlocks both insurance prior authorization (BMI >=30, or >=27 + comorbidity) and NovoCare's $349-$499/mo manufacturer cash-pay program. If you want the tirzepatide molecule for obesity, the correct labeled brand is Zepbound.

Question 4

Is Mounjaro covered by insurance if I'm only obese without diabetes?

Accepted Answer

Almost never. US commercial payers, Medicare Part D, and Medicaid programs uniformly require a documented type 2 diabetes diagnosis (most commonly A1c >=6.5% within the past 12 months) for Mounjaro prior authorization. Obesity-only patients are denied Mounjaro and redirected to Wegovy (if the plan has an obesity benefit) or Zepbound (the FDA-labeled tirzepatide brand for obesity). Lilly's Mounjaro savings card is also restricted to commercially insured patients with a T2D indication — it does not work for cash payers or off-label obesity prescribing.

Question 5

What's the cash price difference between Mounjaro and Wegovy?

Accepted Answer

Wegovy has a manufacturer cash-pay program (NovoCare) at $349/mo for the first two months and $499/mo thereafter for the all-dose pen. Mounjaro has no comparable cash-pay program — the Lilly savings card requires commercial insurance with a T2D diagnosis, leaving cash payers and uninsured patients at ~$1,000-$1,100/mo retail. If cost is the deciding factor and you have an obesity indication (not T2D), Wegovy via NovoCare or Zepbound via LillyDirect ($349/$499 vials) are typically far cheaper than retail Mounjaro.

Question 6

Do Mounjaro and Wegovy have the same side effects?

Accepted Answer

Profiles are similar but not identical. Both are dominated by GI symptoms (nausea, diarrhea, constipation, vomiting) and both carry the same FDA boxed warning for thyroid C-cell tumors. In SURMOUNT-5, the tirzepatide arm reported lower nausea (29%) than the semaglutide arm (44%), though slightly higher discontinuation for adverse events (8% vs 6%). Both also carry signals for pancreatitis, gallbladder disease, and acute kidney injury from dehydration. Titrate slowly to minimize GI tolerability problems regardless of brand.

Field	Mounjaro	Wegovy
FDA-approved indication	Type 2 diabetes only (weight management requires Zepbound)	Chronic weight management; cardiovascular risk reduction in obesity
Mechanism	Dual GIP / GLP-1 receptor agonist	GLP-1 receptor agonist
Weight-loss trial anchor	SURPASS-2: -11.2 kg / 40 wk (15 mg, T2D)	STEP-1: -14.9% TBWL / 68 wk (2.4 mg, obesity)
Head-to-head molecule (SURMOUNT-5)	Tirzepatide -20.2% / 72 wk	Semaglutide -13.7% / 72 wk
Dosing	Once-weekly subq 2.5-15 mg (6-step titration)	Once-weekly subq 0.25-2.4 mg (5-step titration)
Cardiovascular outcome	SURPASS-CVOT pending 2027	MACE -20% in obesity without diabetes (SELECT, 2023)
Cash price (manufacturer direct)	No manufacturer cash-pay program (Lilly savings card limited to commercial T2D insurance)	$349-$499/mo via NovoCare
Insurance coverage path	PA requires A1c >=6.5% + metformin trial; obesity-only patients typically denied	PA requires BMI >=30 (or >=27 + comorbidity); obesity benefit often excluded by employer plans

Mounjaro vs Wegovy (2026): T2D Label vs Obesity Label, Cost

The verdict

Side-by-side comparison

Frequently asked questions